FDA Okays First Biosimilar for Multiple Sclerosis

Sandoz's natalizumab-sztn injection (Tyruko) is on par with Biogen's Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.
Medscape Medical News

source https://www.medscape.com/viewarticle/995845?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?